A recent decision by a federal appeals court has imposed new restrictions on the distribution of mifepristone, a widely used abortion medication in the United States. The court’s ruling prohibits the mailing of mifepristone prescriptions, mandating that the drug be dispensed directly in person at clinics.
The ruling was delivered by a three-judge panel from the 5th U.S. Circuit Court of Appeals in New Orleans. This decision overrides the existing guidelines set by the Food and Drug Administration (FDA), potentially leading to an appeal to the U.S. Supreme Court. The ruling marks a significant shift in abortion policy since the Supreme Court’s 2022 decision to overturn Roe v. Wade, which allowed states to implement abortion bans.
Judge Kyle Duncan, appointed by former President Donald Trump, supported Louisiana’s argument that mailing the drug would undermine the state’s abortion ban. The ruling states, “Every abortion facilitated by FDA’s action cancels Louisiana’s ban on medical abortions and undermines its policy that ‘every unborn child is a human being from the moment of conception and is, therefore, a legal person.’”
Mifepristone’s Role in U.S. Abortions
Mifepristone, approved for use in 2000, is often used in conjunction with misoprostol to terminate early pregnancies. Studies show that a majority of abortions in the U.S. are conducted using medication, with approximately 25% of these prescriptions being obtained through telehealth services.
Surveys have indicated that in states with abortion bans, more women are opting for medication abortions through telehealth rather than traveling to states where the procedure is permitted. Some states led by Democrats have enacted laws to protect telehealth providers from legal repercussions when prescribing to patients in areas with restrictive abortion laws.
Challenges to FDA Authority
The court’s decision challenges the norm of deferring to the FDA’s scientific rulings on drug safety and regulation. Historically, federal courts have seldom overruled FDA decisions. The timeline for the decision’s impact on mifepristone’s availability via mail remains unclear.
In response to safety concerns, the FDA initially enforced strict guidelines for mifepristone distribution, which required in-person appointments. These restrictions were lifted during the COVID-19 pandemic under the Biden administration, after extensive research indicated the drug’s safe use without direct supervision.
GenBioPro, a producer of generic mifepristone, criticized the court’s ruling, stating that it disregards “the FDA’s rigorous science and decades of safe use of mifepristone in a case pursued by extremist abortion opponents.”
National Implications of the Ruling
Louisiana’s attorney general, alongside a woman who claimed coercion into taking abortion pills, called for a rollback to stricter FDA rules. Although a Louisiana-based federal judge recently ruled against immediate changes, the appeals court’s decision extends beyond Louisiana, affecting states where abortion remains legal.
Telehealth prescriptions are common across the nation, and the ruling may limit access to abortion and miscarriage care nationwide. Julia Kaye from the ACLU noted, “When telemedicine is restricted, rural communities, people with low incomes, people with disabilities, survivors of intimate partner violence, and communities of color suffer the most.”
The National Right to Life Committee praised the decision, with President Carol Tobias stating, “Women deserve better than an abortion-by-mail system that prioritizes ideology over safety.”
Potential Supreme Court Involvement
Danco Laboratories, another manufacturer of mifepristone, has requested a delay of the appeals court’s order to allow time for a potential appeal to the Supreme Court. If denied, an emergency appeal will be filed.
The Supreme Court, which has a conservative majority, previously overturned nationwide abortion rights but maintained access to mifepristone in a 2024 decision due to lack of standing from the plaintiffs.
Louisiana Attorney General Liz Murrill commented, “I look forward to continuing to defend women and babies as this case continues.” Representatives from the FDA and the U.S. Department of Justice have not yet responded to requests for comment.
Anti-abortion groups have expressed approval of the ruling. Marjorie Dannenfelser of Susan B. Anthony Pro-Life America called it “a huge victory for victims and survivors of Biden’s reckless mail-order abortion drug regime.”
